Editas Medicine Announces The FDA Has Cleared Initiation Of The EDIT-301 Clinical Trial

Gene editing

Home » Emerging technologies » Gene editing

CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV

-Funding from the Bill & Melinda Gates Foundation will support research to enable CRISPR/Cas9-based therapies for HIV that can benefit patients worldwide- ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE...

Intellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments

Funding from the Bill & Melinda Gates Foundation to develop safe, scalable and accessible non-viral treatments for sickle cell patients CAMBRIDGE, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) — Intellia Therapeutics...

Intellia Therapeutics

Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis

These CRISPR Edited Seeds Are Planting A Sustainable Future For The Agricultural Industry

Recombia Biosciences

Lesaffre and Recombia Biosciences to advance innovative gene editing technology through a strategic partnership

Sri Kosaraju

Inscripta Appoints Sri Kosaraju as President and CEO

Synthego’s CRISPR Platform Enables Faster Identification of Potential Coronavirus Treatment

Synthego Pioneers Next-Generation CRISPR Light Control Technology

Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases, Including Amyotrophic Lateral Sclerosis

Scribe Therapeutics Unveils Fully Integrated Platform for Engineering Breakthrough CRISPR-based Genetic Medicines

Novome Biotechnologies Expands Therapeutic Focus and Platform Capabilities with Acquisition of Preclinical Projects and Intellectual Property from Caribou Biosciences and License to CRISPR-Cas9 Foundational Patent Portfolio

Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline

Elo Life Systems Announces Strategic Partnership with Dole Food Company with the Goal of Saving the Cavendish Banana

CARB-X funds Eligo Bioscience to develop CRISPR-based therapeutics derived from bacteriophages to kill superbugs and prevent deadly infections in transplant patients